BIAF · bioAffinity Technologies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current expected level of operating expenditures and the cash and cash equivalents on hand at June 30, 2026, management concludes that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 7, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Sep 19, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Sep 19, 2025.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| CyPath Lung test reports delivered | 1,097 | first six months of 2026 | — |
| CyPath® Lung diagnostic test volume | 216% | Q2 2026 | — |
| Existing clients increase in CyPath Lung orders | 71% | first six months of 2026 | — |
| Gross proceeds from public offering | $3.2M | Q2 2026 | — |
| Number of physician offices and clinics ordering CyPath Lung for their patients | 122% | Q2 2026 | — |
| Gross proceeds from equity transactions | $16.9M | year ended December 31, 2025 | — |
| Number of CyPath® Lung tests performed | 99% | year ended December 31, 2025 | — |
| Revenue from our noninvasive diagnostic for lung cancer | 87% | year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIAF
this stock
bioAffinity Technologies, Inc.
|
$3.26M | -65.9% | +14.5% | — | 4.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Sep 19, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIAF | -21.2% | -42.9% | -56.8% | -35.9% | -65.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -21.6% | -47.3% | -70.6% | -39.8% | -79.8% |